The effect of aromatase inhibition on the cognitive function of older patients with breast cancer.

ABSTRACT:

Introduction

This study evaluated the association between aromatase inhibitor (AI) therapy and cognitive function (over a 6-month period) in a cohort of patients aged ≥ 60 years compared with an age-matched healthy control group, and it evaluated changes in regional cerebral metabolism as measured by positron emission tomography (PET) scans of the brain done in a subset of the patient cohort.

Patients and methods

Thirty-five patients (32 evaluable) and 35 healthy controls were recruited to this study. Patients with breast cancer completed a neuropsychological battery, self-reported memory questionnaire, and geriatric assessment before initiation of AI therapy and again 6 months later. Age-matched healthy control participants completed the same assessments at the same time po

SUBMITTER: Hurria A 

PROVIDER: S-EPMC4103787 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature